Please select the option that best describes you:
Topics:
Neuro-Oncology • Pediatric Hematology/Oncology • Neurology • Journal Club ft. Nature Publications • Low-Grade Glioma
In pediatric patients with low-grade gliomas showing prolonged response or stable disease on tovorafenib, how would you adjust the duration of therapy?
Are there specific safety concerns or long-term risks that should be accounted for when considering drug holidays or overall treatment duration?
Answer from: at Academic Institution
This is a one-million-dollar question. As far as I know, the design of FIREFLY-2 includes a fixed duration of treatment, and this is also the case for ACSN1833 (selumetinib trial). It will be important to look at the PFS of the patients who discontinued tovorafenib and compare with the results of ch...
Sign in or Register to read more
Answer from: at Academic Institution
In the FIREFLY-1 trial, patients who were benefiting from therapy were treated for at least 26 cycles prior to a drug holiday and then had the option for retreatment if they progressed during the holiday. This is a similar duration of therapy to that used in a number of other clinical trials in this...